Kate Haviland, Blueprint Medicines CEO
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
Blueprint Medicines presented the full dataset for its drug Ayvakit at a medical conference over the weekend as it heads towards an FDA decision in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
